Prognostic Implication of LDL-C Variability and Its Association with Lipid-Lowering Strategies: Insights from the...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Lipid-lowering strategies aim to reduce cardiovascular risk.
• Understanding LDL-C variability is crucial for optimizing treatment.
• Previous trials provide data for comparative analysis.

Purpose of the Study:

• To compare visit-to-visit LDL-C variability across different lipid-lowering strategies.
• To assess the prognostic implications of LDL-C variability on cardiovascular outcomes.

Main Methods:

• Analysis of two randomized clinical trials (RACING and LODESTAR).
• Evaluation of LDL-C variability using standard deviation (SD), coefficient of variation, and variation independent of mean.
• Primary endpoint: composite of death, myocardial infarction, stroke, or coronary revascularization.

Main Results:

• LDL-C variability was similar with moderate-intensity statin plus ezetimibe compared to high-intensity statins.
• Higher LDL-C variability was observed with a treat-to-target strategy.
• Increased LDL-C variability (by SD) independently predicted the primary endpoint (HR 1.024, p<0.001).
• Each 1-SD increase in LDL-C variability was associated with increased risk of MI (2.1%), stroke (3.5%), and revascularization (2.7%).

Conclusions:

• Moderate-intensity statin plus ezetimibe did not increase LDL-C variability compared to high-intensity statins.
• Treat-to-target strategies were associated with increased LDL-C variability.
• Elevated LDL-C variability is linked to higher risks of adverse cardiovascular outcomes, even with guideline-directed statin therapy.